Yes, NEU is unequivocally the stand out risk v reward wise, even compared to ANP, let alone other peers. ANP haven't commenced Phase 2b yet, prior Phase 2a was not double blind, placebo controlled. Phase 2b may or may not be pivotal (uncomfirmed but definitely won't be from an FDA standpoint). NEU need to replicate phase 2a and 2b results for a $10 price tag, per share. Anecdotal results are consistent with Phase 2a and 2b in Retts, which is promising. Said Phase 3 trial is fully funded (at a cost of 75% of market cap) with results 2H21. NEU definitely the standout here, for mine.
NEU Price at posting:
$1.46 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)